118 related articles for article (PubMed ID: 17305500)
1. Targeting the RAS signaling pathway in malignant hematologic diseases.
Morgan MA; Ganser A; Reuter CW
Curr Drug Targets; 2007 Feb; 8(2):217-35. PubMed ID: 17305500
[TBL] [Abstract][Full Text] [Related]
2. Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents.
Minutolo F; Asso V; Bertini S; Betti L; Ciriaco M; Danesi R; Gervasi G; Ghilardi E; Giovanetti E; Giannaccini G; Placanica G; Prota G; Rapposelli S; Macchia M
Med Chem; 2005 May; 1(3):239-44. PubMed ID: 16787319
[TBL] [Abstract][Full Text] [Related]
3. Ras as a therapeutic target in hematologic malignancies.
Alvarado Y; Giles FJ
Expert Opin Emerg Drugs; 2007 May; 12(2):271-84. PubMed ID: 17604501
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
Tamanoi F; Lu J
Enzymes; 2013; 34 Pt. B():181-200. PubMed ID: 25034105
[TBL] [Abstract][Full Text] [Related]
6. Using inhibitors of prenylation to block localization and transforming activity.
Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl Transferase Inhibitors as Potential Anticancer Agents.
Bagchi S; Rathee P; Jayaprakash V; Banerjee S
Mini Rev Med Chem; 2018; 18(19):1611-1623. PubMed ID: 30068272
[TBL] [Abstract][Full Text] [Related]
8. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
9. RAS/RAF/MEK inhibitors in oncology.
Rusconi P; Caiola E; Broggini M
Curr Med Chem; 2012; 19(8):1164-76. PubMed ID: 22257058
[TBL] [Abstract][Full Text] [Related]
10. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
11. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
12. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
Chang F; Steelman LS; Lee JT; Shelton JG; Navolanic PM; Blalock WL; Franklin RA; McCubrey JA
Leukemia; 2003 Jul; 17(7):1263-93. PubMed ID: 12835716
[TBL] [Abstract][Full Text] [Related]
13. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
Kogut MH; Genovese KJ; He H
Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
[TBL] [Abstract][Full Text] [Related]
14. Agents targeting ras signaling pathway.
Dancey JE
Curr Pharm Des; 2002; 8(25):2259-67. PubMed ID: 12369854
[TBL] [Abstract][Full Text] [Related]
15. Modulation of k-Ras signaling by natural products.
Bharate SB; Singh B; Vishwakarma RA
Curr Med Chem; 2012; 19(14):2273-91. PubMed ID: 22414109
[TBL] [Abstract][Full Text] [Related]
16. Increased long-term potentiation in the CA1 region of rat hippocampus via modulation of GTPase signalling or inhibition of Rho kinase.
O'Kane EM; Stone TW; Morris BJ
Neuropharmacology; 2004 May; 46(6):879-87. PubMed ID: 15033347
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Ras pathway in pediatric hematologic malignancies.
Pikman Y; Stieglitz E
Curr Opin Pediatr; 2021 Feb; 33(1):49-58. PubMed ID: 33394740
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
19. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
20. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.
Efuet ET; Keyomarsi K
Cancer Res; 2006 Jan; 66(2):1040-51. PubMed ID: 16424040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
